Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT06164379

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06164379
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06164379. Randomized; double masking; primary purpose treatment. Start 2023-12-16 (anticipated); primary completion 2024-12-16 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism
Acronym
FAVOR
Condition
Primary Aldosteronism
Intervention (Drug)
Finerenone
Intervention (Drug)
Spironolactone
Lead sponsor
Shanghai Jiao Tong University School of Medicine (class: other)

Record details

Record id
cardio:ct-nct06164379
Content hash
78f4f325162a822358dd44bdfbf6cb2e8d28f00417491bcb3ac8e18950154e59